AN OPEN-LABEL INTERVENTIONAL, MULTICENTER, RANDOMIZED, PHASE 2 STUDY OF FULVESTRANT WITH OR WITHOUT SAMURACICLIB IN PARTICIPANTS WITH METASTATIC OR LOCALLY ADVANCED HORMONE RECEPTOR POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER

14727CT7001-002Open (affiliates only)AN OPEN-LABEL INTERVENTIONAL, MULTICENTER, RANDOMIZED, PHASE 2 STUDY OF FULVESTRANT WITH OR WITHOUT SAMURACICLIB IN PARTICIPANTS WITH METASTATIC OR LOCALLY ADVANCED HORMONE RECEPTOR POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCERCT7001_002NCT05963984IndustrialAdultTreatmentIIOtherKurian, ShwetaMedstar Franklin Square Medical Center; Medstar Good Samaritan HospitalBreastOncology GroupMHRI Oncology Baltimore2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>